DEVELOPMENT OF RP-HPLC METHOD FOR ESTIMATION OF DROTAVERINE HYDROCHLORIDE IN PHARMACEUTICAL FORMULATIONS

drotaverine hydrochloride is a novel antispasmodic agent. A simple, selective and precise RPHPLC method was developed for quantification of Drotaver ine hydrochloride in pharmaceutical formulations. The sample was analyzed on reverse phase C18 column (250 mm length, 4. 6 mm internal diameter and 5 8m particle size) by using a fixed composition of mobile phase consisting of 25 millimolar sodium acetate buffer (pH was adjusted to 4.50 with acetic acid after addition of 2 mL of triethyl amine) and acetonitrile in the ratio of 55 : 45 v/v. The mobile phase was passed through the system at a flow rate of 1.0 mL/min and the analyte was monitored with UV detector at 354 nm. The proposed method is having a run time of 12 min with analyte retention time around 7.42 min. The developed method shows linearity in the concentration range of 4-12 8g/mL. The method was validated for use in routine quality control of drotaverine hydrochloride in pharmaceutical formulations.